Snyder David S, McMahon Ross, Cohen Sandra R, Slovak Marilyn L
Division of Hematology/Bone Marrow Transplantation, City of Hope National Medical Center, Duarte, California 91010, USA.
Am J Hematol. 2004 Feb;75(2):92-5. doi: 10.1002/ajh.10456.
A case of a patient with chronic myeloid leukemia whose cells expressed an e13a3 (b2a3) variant BCR-ABL p210 mRNA is presented. The variant splice was detected by a qualitative reverse transcriptase polymerase chain reaction using primers complementary to BCR exon 13 (b2) and ABL exon 3 (a3). The patient responded well to imatinib and achieved a complete cytogenetic response.
本文报告了一例慢性髓性白血病患者，其细胞表达e13a3（b2a3）变异型BCR-ABL p210 mRNA。使用与BCR外显子13（b2）和ABL外显子3（a3）互补的引物，通过定性逆转录酶聚合酶链反应检测到该变异剪接。该患者对伊马替尼反应良好，实现了完全细胞遗传学缓解。
